[14] |
黄伟刚,陈荣策,项嘉亮,等.结直肠癌患者血清中IL-17和IL-6 的表达及其临床意义[J].肿瘤,2012,32(6):458-461.
|
[15] |
陈善传,王丽,董凤珍,等.IL6、IL23、CEA 和CA199 在结直肠癌患者的血清学表达及意义[J].放射免疫学杂志,2011,24(4):444-447.
|
[16] |
张晓芹,段丽芳,党琳,等.IL6 和STAT3 在结肠癌组织中的表达及意义[J].海南医学,2017,28(2):185-187.
|
[1] |
Okada F.Inframmaation-related carcinogenesis:current findings in epidemilolgical trends,causes and mechanisms[J].Yonago Acta Med,2014,57(2):65-72.
|
[2] |
Landskron G,De la Fuente M,et al.Chronic inflammation and cytoki nes in the tumor microenvironment[J].Immunol Res,2014,20(4):149-155.
|
[3] |
Thomas H.IL-6 drives niche formation in pancreatic cancer liver metastasis[J].Nat Rev Gastroenterol Hepatol,2019,16(5):263.
|
[4] |
Sanguinete MMM,Oliveira PH,Martins-Filho A,et al.Serum IL-6 and IL-8 correlate with prognostic factors in ovarian Cancer[J].Immunol Invest,2017,46(4):677-688.
|
[8] |
张晓玲,韩国达,邢荣格.IL-6 在不同Dukks 分期结肠癌中的表达及临床意义[J].现代肿瘤医学,2016,24(14):2256-2259.
|
[12] |
杨阳,杨晶晶,宁宁,等.YKL-40 和IL-6 在结肠癌组织中表达变化的研究[J].安徽医科大学学报,2015,50(6):657-660.
|
[13] |
陈岩松,陈燕,陈娜娟.结直肠癌患者血清白细胞介素6水平及与肿瘤疗效关系[J].标记免疫分析与临床,2017,24(11):1274-1279.
|
[5] |
Ray K,Ujvari B,Ramana V,et al.Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer[J].Cytokine Growth Factor Rev,2018,41(6):18-27.
|
[6] |
Kallio J,Hamalainen M,Luukkaala T,et al.Resistin and interleukin 6 as predictive factors for recurrence and longterm prognosis in renal cell cancer[J].Urol Oncol,2017,35(5):525-544.
|
[7] |
Zeng J,Tang ZH,Liu S,et al.Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer[J].World J Gastroenterol,2017,14(3):1780-1786.
|
[9] |
Matsuo K,Oka M,Murase K,et al.Expression of interieukin 6 and its receptor in human gastric and coiorectai cancer[J].J Int Med Res,2003,31(2):69-75.
|
[10] |
Chung SS,Wu Y,Okobi Q,et al.Proinflammatory Cytokines IL-6 and TNF-alpha Increased Telomerase Activity through NF-kappaB/STAT1/STAT3 Activation,and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells[J].Mediators Inflamm,2019,20(7):59-64.
|
[11] |
Toyoshima Y,Kitamura H,et al.IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells[J].Cancer Immunol Res,2019,7(12):1944-1957.
|
[17] |
Wei N,Li J,Fang C,et al.Targeting colon cancer with the novel STAT3 inhibitor bruceantinol[J].Oncogene. 2019,38(10):1676-1687.
|
[18] |
Lin Y,He Z,Ye J,et al.Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer[J].Onco Targets Ther,2020,21(12):13023-13032.
|